| 摘要 |
Disclosed is a use of a selective cytokine inhibitory drug selected from: 3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide; cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yI}-amide; a compound of formula (I); a compound of formula (II) and a compound of formula (III), wherein the variables are as defined in the specification; or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, in the preparation of a composition for treating or preventing a myeloproliferative disease in a patient. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions comprising the above selective cytokine inhibitory drug and the second active agents are also disclosed, wherein the selective cytokine inhibitory drug and the second active agent are present in the composition in complementary amounts or synergistically effective amounts for the treatment, prevention or management of a myeloproliferative disease.
|
